Patient Characteristics Associated with Buprenorphine/naloxone Treatment Outcome for Prescription Opioid Dependence: Results from a Multisite Study

Overview

Journal Drug Alcohol Depend

Publisher Elsevier

Specialty Psychiatry

Date 2013 Jan 22

PMID 23333292

Citations 67

Authors

Jessica A Dreifuss

Margaret L Griffin

Katherine Frost

Garrett M Fitzmaurice

Jennifer Sharpe Potter

David A Fiellin

Jeffrey Selzer

Mary Hatch-Maillette

Susan C Sonne

Roger D Weiss

Affiliations

Soon will be listed here.

Abstract

Background: Prescription opioid dependence is a growing problem, but little research exists on its treatment, including patient characteristics that predict treatment outcome.

Methods: A secondary analysis of data from a large multisite, randomized clinical trial, the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study (POATS) was undertaken to examine baseline patient characteristics (N=360) associated with success during 12-week buprenorphine/naloxone treatment for prescription opioid dependence. Baseline predictor variables included self-reported demographic and opioid use history information, diagnoses assessed via the Composite International Diagnostic Interview, and historical opioid use and related information from the Pain And Opiate Analgesic Use History.

Results: In bivariate analyses, pre-treatment characteristics associated with successful opioid use outcome included older age, past-year or lifetime diagnosis of major depressive disorder, initially obtaining opioids with a medical prescription to relieve pain, having only used opioids by swallowing or sublingual administration, never having used heroin, using an opioid other than extended-release oxycodone most frequently, and no prior opioid dependence treatment. In multivariate analysis, age, lifetime major depressive disorder, having only used opioids by swallowing or sublingual administration, and receiving no prior opioid dependence treatment remained as significant predictors of successful outcome.

Conclusions: This is the first study to examine characteristics associated with treatment outcome in patients dependent exclusively on prescription opioids. Characteristics associated with successful outcome after 12 weeks of buprenorphine/naloxone treatment include some that have previously been found to predict heroin-dependent patients' response to methadone treatment and some specific to prescription opioid-dependent patients receiving buprenorphine/naloxone.

Citing Articles

Protocol for harmonization of randomized trials testing the addition of behavioral therapy to buprenorphine for opioid use disorder.

McHugh R, Bailey A, Weiss R, Fitzmaurice G Drug Alcohol Depend Rep. 2024; 11:100226.

PMID: 38545409 PMC: 10966146. DOI: 10.1016/j.dadr.2024.100226.

Cognitive behavioral therapy for anxiety and opioid use disorder: Development and pilot testing.

McHugh R, Fitzmaurice G, Votaw V, Geyer R, Ragnini K, Greenfield S J Subst Use Addict Treat. 2024; 160:209296.

PMID: 38272120 PMC: 11060910. DOI: 10.1016/j.josat.2024.209296.

Recent Opioid Use Impedes Range Adaptation in Reinforcement Learning in Human Addiction.

Gueguen M, Anllo H, Bonagura D, Kong J, Hafezi S, Palminteri S Biol Psychiatry. 2023; 95(10):974-984.

PMID: 38101503 PMC: 11065633. DOI: 10.1016/j.biopsych.2023.12.005.

Prevalence of Current Restless Legs Syndrome Symptoms Among Patients Treated with Buprenorphine/Naloxone for Opioid Use Disorder.

Wipper B, Cooke M, Winkelman J Nat Sci Sleep. 2023; 15:851-859.

PMID: 37886689 PMC: 10599248. DOI: 10.2147/NSS.S427403.

Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder.

Reed M, Murali V, Sarpoulaki N, Zavodnick J, Hom J, Rising K Drug Alcohol Depend Rep. 2023; 5:100106.

PMID: 36844165 PMC: 9948932. DOI: 10.1016/j.dadr.2022.100106.

References

Petry N, Bickel W . Therapeutic alliance and psychiatric severity as predictors of completion of treatment for opioid dependence. Psychiatr Serv. 1999; 50(2):219-27. DOI: 10.1176/ps.50.2.219. View

Teesson M, Mills K, Ross J, Darke S, Williamson A, Havard A . The impact of treatment on 3 years' outcome for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Addiction. 2007; 103(1):80-8. DOI: 10.1111/j.1360-0443.2007.02029.x. View

George O, Koob G . Individual differences in prefrontal cortex function and the transition from drug use to drug dependence. Neurosci Biobehav Rev. 2010; 35(2):232-47. PMC: 2955797. DOI: 10.1016/j.neubiorev.2010.05.002. View

Rao S, Broome K, Simpson D . Depression and hostility as predictors of long-term outcomes among opiate users. Addiction. 2004; 99(5):579-89. DOI: 10.1111/j.1360-0443.2004.00686.x. View

Joe G, SIMPSON D, Sells S . Treatment process and relapse to opioid use during methadone maintenance. Am J Drug Alcohol Abuse. 1994; 20(2):173-97. DOI: 10.3109/00952999409106781. View

Chatham L, Joe G, SIMPSON D . Heavy drinking, alcohol-dependent vs. nondependent methadone-maintenance clients: a follow-up study. Addict Behav. 1997; 22(1):69-80. DOI: 10.1016/s0306-4603(96)00005-6. View

Dackis C, Gold M . Pharmacological approaches to cocaine addiction. J Subst Abuse Treat. 1985; 2(3):139-45. DOI: 10.1016/0740-5472(85)90043-1. View

Petry N, Bickel W . Gender differences in hostility of opioid-dependent outpatients: role in early treatment termination. Drug Alcohol Depend. 2000; 58(1-2):27-33. DOI: 10.1016/s0376-8716(99)00058-7. View

Joe G, SIMPSON D, Broome K . Retention and patient engagement models for different treatment modalities in DATOS. Drug Alcohol Depend. 2000; 57(2):113-25. DOI: 10.1016/s0376-8716(99)00088-5. View

10.

Zacny J, Lichtor S . Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. Psychopharmacology (Berl). 2007; 196(1):105-16. PMC: 2562738. DOI: 10.1007/s00213-007-0937-2. View

11.

SIMPSON D, Joe G . Drug abuse treatment retention and process effects on follow-up outcomes. Drug Alcohol Depend. 1997; 47(3):227-35. DOI: 10.1016/s0376-8716(97)00099-9. View

12.

Flynn P, Joe G, Broome K, Simpson D, Brown B . Recovery from opioid addiction in DATOS. J Subst Abuse Treat. 2003; 25(3):177-86. DOI: 10.1016/s0740-5472(03)00125-9. View

13.

Pani P, Maremmani I, Pirastu R, Tagliamonte A, Gessa G . Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 2000; 60(1):39-50. DOI: 10.1016/s0376-8716(99)00140-4. View

14.

Sigmon S . Characterizing the emerging population of prescription opioid abusers. Am J Addict. 2006; 15(3):208-12. DOI: 10.1080/10550490600625624. View

15.

Backmund M, Meyer K, Eichenlaub D, Schutz C . Predictors for completing an inpatient detoxification program among intravenous heroin users, methadone substituted and codeine substituted patients. Drug Alcohol Depend. 2001; 64(2):173-80. DOI: 10.1016/s0376-8716(01)00122-3. View

16.

Wells-Parker E, Williams M . Enhancing the effectiveness of traditional interventions with drinking drivers by adding brief individual intervention components. J Stud Alcohol. 2003; 63(6):655-64. DOI: 10.15288/jsa.2002.63.655. View

17.

Mancino M, Curran G, Han X, Allee E, Humphreys K, Booth B . Predictors of attrition from a national sample of methadone maintenance patients. Am J Drug Alcohol Abuse. 2010; 36(3):155-60. PMC: 3314423. DOI: 10.3109/00952991003736389. View

18.

Heinzerling K, McCracken J, Swanson A, Ray L, Shoptaw S . COMT Val158Met, BDNF Val66Met, and OPRM1 Asn40Asp and methamphetamine dependence treatment response: preliminary investigation. J Clin Psychopharmacol. 2012; 32(1):135-7. PMC: 3597465. DOI: 10.1097/JCP.0b013e318240a48e. View

19.

Wells-Parker E, Dill P, Williams M, Stoduto G . Are depressed drinking/driving offenders more receptive to brief intervention?. Addict Behav. 2005; 31(2):339-50. DOI: 10.1016/j.addbeh.2005.05.011. View

20.

Peles E, Schreiber S, Adelson M . 15-Year survival and retention of patients in a general hospital-affiliated methadone maintenance treatment (MMT) center in Israel. Drug Alcohol Depend. 2009; 107(2-3):141-8. DOI: 10.1016/j.drugalcdep.2009.09.013. View